Reddy JA[au] - Search Results

Year	Number of Results
1998	2
1999	2
2000	1
2001	1
2002	4
2003	1
2004	3
2005	3
2006	3
2007	5
2008	2
2009	1
2010	2
2011	2
2012	1
2013	1
2014	3
2016	2
2017	2
2018	1
2019	2
2020	1
2021	1
2022	0

1

Folate-targeted chemotherapy.

Leamon CP, Reddy JA. Leamon CP, et al. Among authors: reddy ja. Adv Drug Deliv Rev. 2004 Apr 29;56(8):1127-41. doi: 10.1016/j.addr.2004.01.008. Adv Drug Deliv Rev. 2004. PMID: 15094211 Review.

2

The folate receptor as a rational therapeutic target for personalized cancer treatment.

Assaraf YG, Leamon CP, Reddy JA. Assaraf YG, et al. Among authors: reddy ja. Drug Resist Updat. 2014 Oct-Dec;17(4-6):89-95. doi: 10.1016/j.drup.2014.10.002. Epub 2014 Oct 8. Drug Resist Updat. 2014. PMID: 25457975 Review.

3

"Stealth" retro-auricular endoscopic surgery for a submandibular mass.

J S R, Reddy JA, Vijayan RK, Kharip Z, Sisodiya R, Eraki M. J S R, et al. Among authors: reddy ja. Int J Surg Case Rep. 2021 Mar;80:105677. doi: 10.1016/j.ijscr.2021.105677. Epub 2021 Feb 23. Int J Surg Case Rep. 2021. PMID: 33652365 Free PMC article.

4

Targeting therapeutic and imaging agents to folate receptor positive tumors.

Reddy JA, Allagadda VM, Leamon CP. Reddy JA, et al. Curr Pharm Biotechnol. 2005 Apr;6(2):131-50. doi: 10.2174/1389201053642376. Curr Pharm Biotechnol. 2005. PMID: 15853692 Review.

5

Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.

Reddy JA, Dorton R, Bloomfield A, Nelson M, Dircksen C, Vetzel M, Kleindl P, Santhapuram H, Vlahov IR, Leamon CP. Reddy JA, et al. Sci Rep. 2018 Jun 12;8(1):8943. doi: 10.1038/s41598-018-27320-5. Sci Rep. 2018. PMID: 29895863 Free PMC article.

6

Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate.

Leamon CP, Reddy JA, Bloomfield A, Dorton R, Nelson M, Vetzel M, Kleindl P, Hahn S, Wang K, Vlahov IR. Leamon CP, et al. Among authors: reddy ja. Bioconjug Chem. 2019 Jun 19;30(6):1805-1813. doi: 10.1021/acs.bioconjchem.9b00335. Epub 2019 May 22. Bioconjug Chem. 2019. PMID: 31075200

7

Folate-mediated targeting of therapeutic and imaging agents to cancers.

Reddy JA, Low PS. Reddy JA, et al. Crit Rev Ther Drug Carrier Syst. 1998;15(6):587-627. Crit Rev Ther Drug Carrier Syst. 1998. PMID: 9883391 Review.

8

Detecting Functional and Accessible Folate Receptor Expression in Cancer and Polycystic Kidneys.

Chu H, Shillingford JM, Reddy JA, Westrick E, Nelson M, Wang EZ, Parker N, Felten AE, Vaughn JF, Xu LC, Lu YJ, Vlahov IR, Leamon CP. Chu H, et al. Among authors: reddy ja. Mol Pharm. 2019 Sep 3;16(9):3985-3995. doi: 10.1021/acs.molpharmaceut.9b00624. Epub 2019 Aug 13. Mol Pharm. 2019. PMID: 31356752

9

Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent.

Reddy JA, Nelson M, Dircksen C, Vetzel M, Johnson T, Cross V, Westrick E, Qi L, Hahn S, Santhapuram HK, Parham G, Wang K, Vaughn JF, Felten A, Pugh M, Lu J, Klein P, Vlahov IR, Leamon CP. Reddy JA, et al. Sci Rep. 2020 Jul 29;10(1):12772. doi: 10.1038/s41598-020-69682-9. Sci Rep. 2020. PMID: 32728172 Free PMC article.

10

Dapsone-induced acute pancreatitis.

Jha SH, Reddy JA, Dave JK. Jha SH, et al. Among authors: reddy ja. Ann Pharmacother. 2003 Oct;37(10):1438-40. doi: 10.1345/aph.1C482. Ann Pharmacother. 2003. PMID: 14519046

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results